Discover the latest news about our company and products
June 28, 2021 Press Release
Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting
January 19, 2021 Press Release
December 30, 2020 Press Release
December 14, 2020 Press Release
December 1, 2020 Press Release
August 31, 2020 Press Release
August 24, 2020 Press Release
July 15, 2020
New publication highlights potential of nanotechnology in the development of a COVID-19 vaccine. The manuscript titled "COVID-19 vaccine development and a potential nanomaterial path forward" was published in the July 15 edition of Nature Nanotechnology and highlighted the potential of plant made vaccines and microneedle delivery systems which are part of Mosaic IE's technology portfolio.
May 04, 2020
New publication highlights the potential of Mosaic IE's lead oncology candidate MIE-101 in combination with immune checkpoint inhibitors. The manuscript titled "A Combination of Cowpea Mosaic Virus and Immune Checkpoint Therapy Synergistically Improves Therapeutic Efficacy in Three Tumor Models" was published in the May 4 edition of Advanced Functional Materials. Results published in the article highlighted the synergistic anti-tumor effects of combining MIE-101 with PD-1 and OX40 checkpoint blockade. The combination of MIE-101 and a PD-1 inhibitor also resulted in 100% survival following a subsequent tumor re-challenge.
April 20, 2020
Researchers at the University of California San Diego received a Rapid Response Research (RAPID) grant from the National Science Foundation to study scalable manufacturing of a microneedle coronavirus vaccine delivery system which can be used as part of Mosaic IE's modular vaccine platform (NSF Award #2027668)